Magneto-controlled electrochemical immunosensing platform to assess the senescence-associated GDF-15 marker in colorectal cancer

  1. Sandra Tejerina-Miranda 2
  2. Víctor Pérez-Ginés 2
  3. Rebeca M. Torrente-Rodríguez 2
  4. María Pedrero 2
  5. Ana Montero-Calle 1
  6. José M. Pingarrón 2
  7. Rodrigo Barderas 1
  8. Susana Campuzano 2
  1. 1 Chronic Disease Programme, UFIEC, Institute of Health Carlos III, Majadahonda, 28220-Madrid, Spain
  2. 2 Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, 28040-Madrid, Spain
Revista:
Sensors & Diagnostics

ISSN: 2635-0998

Año de publicación: 2024

Tipo: Artículo

DOI: 10.1039/D3SD00311F GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Sensors & Diagnostics

Resumen

In this study, we report a novel electrochemical immunoplatform using magnetic micro-supports and screen-printed carbon electrodes (SPCEs), overcoming limitations of the methods reported to date, for the rapid and sensitive determination of GDF-15, a molecular marker associated with cellular senescence in aging and cancer development and prognosis. The immunoplatform incorporated a sandwich-type configuration with specific capture and biotinylated-detection antibodies and used a streptavidin–peroxidase (strep–HRP) enzymatic conjugate as label. After magnetic capturing the micro-supports with the sandwich HRP-labeled immunocomplexes onto the surface of a SPCE, the change in cathodic current was quantified in the presence of H2O2 and hydroquinone (HQ), showing a direct correlation with the GDF-15 concentration. The proposed bioplatform exhibited attractive performance characteristics, including a good reproducibility (RSD 4.3%), and a wide linear concentration dynamic range from 140 to 10 000 pg mL−1 with a low limit of detection (LOD) of 42 pg mL−1 for GDF-15 standards in buffered solutions. The selectivity of the developed method and the storage stability of the capturing immunoconjugates were noteworthy. Indeed, the immunoconjugates showed a reliable performance for over 28 days when stored in a refrigerator. The immunoplatform was applied to a cohort of 19 plasma samples representing the different stages of colorectal cancer (CRC). The method allowed efficient discrimination between healthy individuals and CRC patients, particularly those in advanced stages, within a rapid 75-minute timeframe. The immunoplatform also presents substantial advantages in terms of cost-effectiveness, assay time reduction, and simplicity compared to other available techniques.